|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
immune modulation
|
|
gptkbp:approves
|
gptkb:2017
|
|
gptkbp:clinical_trial
|
multiple sites
overall survival
progression-free survival
NC T03012345
|
|
gptkbp:collaborations
|
gptkb:healthcare_organization
|
|
gptkbp:developed_by
|
Agenus
|
|
gptkbp:dosage_form
|
dose escalation
|
|
gptkbp:frequency
|
once every 3 weeks
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
AGS-101
|
|
gptkbp:indication
|
solid tumors
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_tested_for
|
Phase 1
PD-L1 expression
|
|
gptkbp:manager
|
intravenous
|
|
gptkbp:market
|
not yet approved
|
|
gptkbp:products
|
IND 123456
|
|
gptkbp:publishes
|
gptkb:The_Lancet_Oncology
gptkb:Clinical_Cancer_Research
gptkb:Nature_Reviews_Cancer
gptkb:Annals_of_Oncology
gptkb:Cancer_Research
gptkb:Frontiers_in_Oncology
gptkb:Journal_of_Clinical_Oncology
gptkb:Journal_of_Immunotherapy
gptkb:vaccine
Cancer Immunology Research
|
|
gptkbp:receives_funding_from
|
government grants
private investment
|
|
gptkbp:research
|
completed
|
|
gptkbp:research_areas
|
gptkb:Johns_Hopkins_University
oncology
|
|
gptkbp:research_focus
|
oncology
|
|
gptkbp:safety_features
|
under evaluation
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
fever
chills
|
|
gptkbp:status
|
gptkb:legal_case
|
|
gptkbp:student_enrollment
|
age 18 or older
informed consent required
no prior chemotherapy
measurable disease required
|
|
gptkbp:target_audience
|
adult patients
|
|
gptkbp:targets
|
gptkb:healthcare_organization
|
|
gptkbp:treatment
|
with checkpoint inhibitors
|
|
gptkbp:type
|
gptkb:vaccine
|
|
gptkbp:bfsParent
|
gptkb:Game_Boy_Advance_SP
|
|
gptkbp:bfsLayer
|
5
|